The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...

Me's sale to Regeneron transfers genetic data for drug development, raising privacy issues and concerns over consumer control ...

Regeneron Pharmaceuticals will acquire embattled DNA testing company 23andMe in a $256 million court-supervised sale, promising to honor existing privacy protections and continue consumer services ...

The sale was for $256 million and is expected to be complete by the third quarter of this year, according to a Regeneron news ...

In March, 23andMe said that it was looking to sell “substantially all of its assets” through a court-approved reorganization plan.

Regeneron Pharmaceuticals said in a press release yesterday that it would acquire 23andMe’s Personal Genome Service (PGS), ...

The US’s credit rating took a hit on Friday, after Moody’s downgraded the country’s AAA rating. And then yesterday, bond ...

Bankrupt DNA testing company 23andMe was purchased Monday by biotechnology company Regeneron for $256 million. Both companies ...

Your DNA results are in — and they're 100% the property of a pharmaceutical manufacturer. It was announced today that 23andMe ...

The DNA testing firm 23andMe says it has entered into an agreement to be acquired by Regeneron Pharmaceuticals for $256m ...

The FTSE 100 , US markets and European stocks were mixed on Monday, as a new deal was struck between the EU and UK and ...

Regeneron Pharmaceuticals has agreed to buy 23andMe for $256 million and plans to continue consumer DNA testing services without interruption.